Delzicol

Drug Overview

DELZICOL, containing the active ingredient Mesalamine, is a core therapeutic agent in the Gastroenterology field and the Drug Class of 5-AMINOSALICYLATES (5-ASA). It is a specialized, delayed-release formulation designed to treat inflammation specifically within the lower gastrointestinal tract. As a Small Molecule anti-inflammatory, it is a primary Targeted Therapy for long-term disease management.

• Generic Name: Mesalamine (5-ASA)
• US Brand Names: Delzicol, Asacol HD, Lialda, Pentasa
• Route of Administration: Oral (Delayed-release capsules)
• FDA Approval Status: FDA-approved for the treatment of mildly to moderately active ulcerative colitis and for the Maintenance of Remission in Ulcerative Colitis in adults and pediatric patients aged 5 years and older.

Delzicol utilizes a pH-dependent enteric coating. This “Dual-Action” delivery system ensures the medication bypasses the acidic environment of the stomach and the enzymes of the small intestine, releasing the active drug only when it reaches the terminal ileum and colon. This supports the stability of the Intestinal Epithelial Barrier for patients requiring chronic maintenance.

What Is It and How Does It Work? (Mechanism of Action)

The effectiveness of Delzicol in managing Ulcerative Colitis is due to its localized effect on the immune cells residing in the gut wall.

1. pH-Dependent Delivery

The Delzicol capsule is coated with an acrylic based resin (Eudragit S) that dissolves only when the surrounding environment reaches a pH of 7 or greater. This specific alkalinity is typically found in the terminal ileum (the end of the small intestine) and the colon. This ensures that the 5-ASA is delivered directly to the site of the disease.

2. Local Anti-Inflammatory Pathways

Once released, Mesalamine works via several mechanisms:

• Inhibition of Cyclooxygenase (COX): It reduces the production of pro-inflammatory prostaglandins.
• Lipoxygenase (LOX) Inhibition: It decreases the levels of leukotrienes, which are potent chemical signals that recruit white blood cells to the gut lining.
• Scavenging Free Radicals: It neutralizes reactive oxygen species that cause oxidative stress and damage to the Intestinal Epithelial Barrier.

3. Mucosal Integrity

By dampening the local immune response, Delzicol promotes Mucosal Healing. It allows the ulcerated areas of the colon to repair, reducing symptoms like rectal bleeding and urgency while preventing future “flares” by keeping the immune system in a state of balance.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved use for Delzicol is:

• Maintenance of Remission in Ulcerative Colitis: Preventing the return of symptoms in patients whose disease is currently inactive.
• Treatment of Mild-to-Moderate Active UC: Induction of clinical response in patients experiencing a flare.

Other Approved & Off-Label Uses

• Pediatric Ulcerative Colitis: Specifically approved for children aged 5 years and older for both treatment and maintenance.
• Crohn’s Disease (Off-label): Occasionally used for mild “colonic” Crohn’s, though evidence for efficacy in Crohn’s is generally weaker than in UC.
• Diverticulitis (Off-label): Sometimes utilized in chronic recurrent diverticulitis to reduce low-grade mucosal inflammation.

Dosage and Administration Protocols

Delzicol capsules must be swallowed whole. They should not be crushed or chewed, as this would destroy the pH-sensitive coating and cause the drug to release prematurely in the stomach.

Dosage Adjustments and Specific Populations

• Renal Impairment: Mesalamine is known to be nephrotoxic. Patients with pre-existing kidney disease require Vigilance and frequent monitoring of serum creatinine and eGFR.
• Hepatic Impairment: Use with caution in patients with liver failure, as the drug is metabolized by the liver.
• Administration with Food: Delzicol can be taken with or without food.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical trials and long-term observational data (2020–2026) confirm that consistent 5-ASA therapy is the gold standard for maintaining remission.

• Remission Maintenance: In pivotal trials, approximately 70% of patients remained flare-free over 12 months while on maintenance Delzicol, compared to only 40% in the placebo group.
• Endoscopic Healing: Research shows that long-term use is associated with “Deep Remission”—a state where the Mayo Endoscopic Score reaches 0 or 1.
• Chemoprevention: Large-scale data suggest that patients who are adherent to their 5-ASA maintenance therapy have a 50% lower risk of developing colorectal cancer compared to non-adherent patients.
• Microbiome Impact: Recent studies indicate that 5-ASA therapy supports a more diverse Gut Microbiome by reducing the inflammatory environment that favors pathogenic bacteria.

Safety Profile and Side Effects

Delzicol does not have a Black Box Warning, but it requires monitoring for kidney health.

Common Side Effects (>10%)

• Abdominal Pain: Often mild and transient.
• Eructation (Burping): Related to the capsule breakdown.
• Nausea: Usually resolves with continued use or taking with food.
• Headache: Reported by a small percentage of users.

Serious Adverse Events

• Renal Impairment: Potential for interstitial nephritis or kidney stones.
• Mesalamine-Induced Acute Intolerance Syndrome: Symptoms include cramping, bloody diarrhea, fever, and rash. If these occur, the drug must be stopped immediately.
• Hepatotoxicity: Rare cases of liver enzyme elevation.
• Pancolitis/Myocarditis: Extremely rare inflammatory reactions of the heart muscle.

Management Strategies

Patients should have their kidney function checked before starting therapy and periodically thereafter (e.g., every 6–12 months). Vigilance is required regarding salicylate (aspirin) allergies; patients with an aspirin allergy should generally avoid Delzicol.

Research Areas

Current Research Areas focus on “Personalized 5-ASA Therapy” and the Gut-Brain Axis.

Recent research (2024–2026) is investigating whether certain genetic markers can predict which patients are most likely to experience “Mesalamine Intolerance.” Scientists are also exploring the impact of 5-ASA on Mucosal Immunology, specifically how it influences “T-cell” exhaustion in the gut wall to maintain long-term peace between the immune system and the Gut Microbiome.

Other active trials are evaluating “Combination Maintenance,” where Delzicol is used alongside specific probiotics (like Akkermansia muciniphila) to see if the combined approach provides even stronger protection for the Intestinal Epithelial Barrier.

Disclaimer: Research regarding the influence of genetic markers on mesalamine intolerance and the co-administration of Akkermansia muciniphila with 5-ASA is currently in the investigative phase and is not yet standard clinical practice. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Perform a baseline serum creatinine, BUN, and urinalysis.
• Organ Function: Screen for pre-existing liver disease.
• Specialized Testing: Assess for a history of aspirin allergy.
• Screening: Review the patient’s colonoscopy history to document the extent of the disease.

Monitoring and Precautions

• Vigilance: Instruct patients that if they see “intact” capsules in their stool, they should notify their doctor, as this may indicate the drug is not dissolving properly.
• Lifestyle: Emphasize that “maintenance” means taking the drug even when feeling well.
• Hydration: Maintain adequate fluid intake to reduce the risk of kidney stones.

“Do’s and Don’ts” list

• DO take your medication at the same time every day to maintain steady levels.
• DO notify your doctor if you develop a new fever or unexplained worsening of diarrhea.
• DON’T crush, chew, or break the Delzicol capsules.
• DON’T stop the medication without consulting your gastroenterologist, as this often leads to a rapid flare of the disease.

Legal Disclaimer

This guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Always seek the advice of your physician or other qualified health practitioner with any questions you may have regarding a medical condition or the use of medications. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.